Company: LGNZZ
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0000886163-25-000036
Chunk: 0

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-05-09
Form: 10-Q
Item: Item 5
Chunk 0
---
Item 5.    Other Information

Rule 10b5-1 Trading Arrangements

From time to time, our officers (as defined in Rule 16a–1(f) of the Exchange Act) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K).

On March 7, 2025, John Kozarich, our Director and Chairman of the Board, executed a 10b5-1 trading arrangement that is designed to be in effect until May 1, 2026 with respect to the sale of up to 5,604 shares of the Company’s common stock all of which underlie stock options held by Mr. Kozarich. Through May 8, 2025, Mr. Kozarich has not sold any shares under the plan.

35